Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection

A Ferreira, A Oliveira-e-Silva, P Bettencourt
doi: https://doi.org/10.1101/2020.06.26.20056507
A Ferreira
1Unidade de Investigação Cardiovascular (UniC), Faculdade de Medicina da Universidade do Porto, Centro Hospitalar Universitário de São João, Porto, and Hospital Rainha Santa Isabel, Marco de Canaveses, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: aloboferreira@gmail.com
A Oliveira-e-Silva
2Hospital de Braga, Braga, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P Bettencourt
3Unidade de Investigação Cardiovascular (UniC), Faculdade de Medicina da Universidade do Porto and Hospital CUF, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Hydroxychloroquine sulphate (HCQ) is being scrutinized for repositioning in the treatment and prevention of SARS-Cov-2 infection. This antimalarial drug is also chronically used to treat patients with autoimmune diseases.

Methods By analyzing the Portuguese anonymized data on private and public based medical prescriptions we have identified all cases chronically receiving HCQ for the management of diseases such as systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases. Additionally, we have detected all laboratory confirmed cases of SARS-CoV-2 infection and all laboratory confirmed negative cases in the Portuguese population (mandatorily registered in a centrally managed database). Cross linking the two sets of data has allowed us to compare the proportion of HCQ chronic treatment (at least 2 grams per month) in laboratory confirmed cases of SARS-CoV-2 infection with laboratory confirmed negative cases.

Results Out of 26,815 SARS-CoV-2 positive patients, 77 (0.29%) were chronically treated with HCQ, while 1,215 (0.36%) out of 333,489 negative patients were receiving it chronically (P=0.04). After adjustment for age, sex, and chronic treatment with corticosteroids and/or immunosuppressants, the odds ratio of SARS-CoV-2 infection for chronic treatment with HCQ has been 0.51 (0.37-0.70).

Conclusions Our data suggest that chronic treatment with HCQ confer protection against SARS-CoV-2 infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Databases with the raw data and a structured database for analysis will be available for the reviewing process.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 29, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection
A Ferreira, A Oliveira-e-Silva, P Bettencourt
medRxiv 2020.06.26.20056507; doi: https://doi.org/10.1101/2020.06.26.20056507
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection
A Ferreira, A Oliveira-e-Silva, P Bettencourt
medRxiv 2020.06.26.20056507; doi: https://doi.org/10.1101/2020.06.26.20056507

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (452)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (158)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5268)
  • Forensic Medicine (3)
  • Gastroenterology (196)
  • Genetic and Genomic Medicine (759)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (699)
  • Health Policy (360)
  • Health Systems and Quality Improvement (224)
  • Hematology (99)
  • HIV/AIDS (164)
  • Infectious Diseases (except HIV/AIDS) (5889)
  • Intensive Care and Critical Care Medicine (363)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (767)
  • Nursing (43)
  • Nutrition (131)
  • Obstetrics and Gynecology (143)
  • Occupational and Environmental Health (234)
  • Oncology (480)
  • Ophthalmology (152)
  • Orthopedics (39)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (98)
  • Psychiatry and Clinical Psychology (864)
  • Public and Global Health (2021)
  • Radiology and Imaging (349)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)